ST6GAL1-IN-1

ST6GAL1-IN-1 is an orally active selective ST6GAL1 inhibitor (IC50 = 20 μM) . ST6GAL1-IN-1 exhibits high antimetastatic potential, effectively inhibiting the migration of MDA-MB-231 cells at noncytotoxic concentrations. ST6GAL1-IN-1 can disrupt integrin sialylation in MDA-MB-231 cells. ST6GAL1-IN-1 inhibits tumor angiogenesis and cancer metastasis via the Integrin/VEGFR2-mediated signaling pathway. ST6GAL1-IN-1 effectively suppresses both tumor growth and cancer metastasis on the MDA-MB-231 xenograft model. ST6GAL1-IN-1 can be used for the study of Triple-negative breast cancer (TNBC) [1].

Product Specifications

CAS Number

[192876-13-4]

UNSPSC

12352005

Target

Akt; Integrin; Sialyltransferase; VEGFR

Related Pathways

Cytoskeleton; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.22

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(N[C@H](C(O)=O)CC3=CNC4=CC=CC=C34)=O)([H])[C@@]5([H])[C@@](CC1)([H])[C@@]6([C@](C[C@@H](CC6)O)([H])CC5)C

Molecular Formula

C35H50N2O4

Molecular Weight

562.78

References & Citations

[1]Chen WS, et al. Optimizing ST6GAL1 inhibition and selectivity using lithocholic acid-amino acid conjugates for antimetastatic and antiangiogenic agent development. Bioorg Chem. 2025 Jun 1;159:108401.